Analyst Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report) and keeping the price target at $50.00.
Tara Bancroft’s rating is based on TG Therapeutics’ impressive financial performance and growth potential. The company reported net revenue for Briumvi in 2024 that surpassed expectations, indicating strong market demand and effective management strategies. The management’s guidance for 2025 suggests continued growth, with projected net revenue figures that could be conservative if the current trends persist.
Moreover, the company’s efforts to enhance Briumvi’s market penetration through strategic initiatives such as expanding treatment centers and engaging directly with patients are noteworthy. The increased recognition and trust in Briumvi among healthcare professionals, particularly in academic hospitals, further support the positive outlook. These factors collectively contribute to Tara Bancroft’s Buy rating for TG Therapeutics.
According to TipRanks, Bancroft is an analyst with an average return of -8.2% and a 26.21% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Protagonist Therapeutics, and TG Therapeutics.
In another report released on March 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.